Author:
Pasciak Alexander S.,Abiola Godwin,Liddell Robert P.,Crookston Nathan,Besharati Sepideh,Donahue Danielle,Thompson Richard E.,Frey Eric,Anders Robert A.,Dreher Matthew R.,Weiss Clifford R.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference38 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):393-424,
2. Fidelman N, Kerlan RK. Transarterial chemoembolization and 90y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease. Am J Roentgenol. 2015;205(4):742-52.
3. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-63.
4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, RTP P, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71
5. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-39.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献